Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says - 2Instructions to Warmly greet Certainty and Appeal
- 3Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- 4Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- 5A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- Some gifted dogs can learn new toy names by eavesdropping on owners
- Far-right German youth group delegates seek deportations, remigration
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- The Solution to Individual budget: Dominating Cash The board
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- 6 Shades Brands For Seniors
